2026-08-29T17:24:48Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/141662025-05-07T09:11:15Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Kissling, Esther author Hooiveld, Mariëtte author Sandonis-Martin, Virginia author Martínez-Baz, Iván author William, Naoma author Vilcu, Ana-Maria author Mazagatos, Clara author Domegan, Lisa author de Lusignan, Simon author Meijer, Adam author Machado, Ausenda author Brytting, Mia author Casado, Itziar author Murray, Josephine-L K author Belhillil, Sylvie author Larrauri, Amparo author O'Donnell, Joan author Tsang, Ruby author de Lange, Marit author Rodrigues, Ana Paula author Riess, Maximilian author Castilla Catalán, Jesús author Hamilton, Mark author Falchi, Alessandra author Pozo Sanchez, Francisco author Dunford, Linda author Cogdale, Jade author Jansen, Tessa author Guiomar, Raquel author Enkirch, Theresa author Burgui, Cristina author Sigerson, Debbie author Blanchon, Thierry author Martínez Ochoa, Eva María author Connell, Jeff author Ellis, Joanna author van Gageldonk-Lafeber, Rianne author Kislaya, Irina author Rose, Angela Mc author Valenciano, Marta author I-MOVE-COVID-19 primary care study team author 2021 We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals. Euro Surveill. 2021;26(29):2100670. 10.2807/1560-7917.ES.2021.26.29.2100670 1560-7917 Euro Surveillance: bulletin Europeen sur les maladies transmissibles 34296676 http://hdl.handle.net/20.500.12105/14166 COVID-19 Europe SARS-CoV-2 Multicentre study Test-negative design Vaccine effectiveness Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021